Biogen’s tofersen fails to meet the primary goal in the Phase III ALS trial
Biogen has announced that its investigational antisense drug, tofersen (BIIB067), flunked to meet the primary goal of Phase III VALOR clinical trial in superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) patients.
Although the drug did not reach the primary goal, the company says that trends favouring tofersen were observed across various secondary and exploratory measures of biologic activity, and clinical function.
Tofersen was licensed by Biogen from Ionis Pharmaceuticals under a collaborative development and licence agreement.
The randomised, placebo-controlled, d...
